Interventions for Reading Disabilities in NF1

Status Recruiting

Clinical Trial Summary

Neurofibromatosis Type 1 (NF1) is a common genetic disorder that is associated with a four times greater risk of learning disabilities, including reading disabilities, and a deficiency of neurofibromin - a protein important in a signaling pathway that regulates learning and memory. Our previous work (NS49096) demonstrated that school-age children with NF+RD can respond to standard phonologically-based reading tutoring originally developed to treat reading disability in the general population. Combining our work with that by other researchers suggesting that a medication (Lovastatin) may counteract the effects of the deficient neurofibromin, and possibly ameliorate learning disabilities in NF1, the investigator propose to examine the synergistic effects of medication plus reading tutoring.

Clinical Trial Description

Neurofibromitosis Type 1 (NF1) is a common autosomal dominant neurocutaneous syndrome. The most common concern of NF1 is learning disabilities (LDs). Approximately half of children with NF1 have LDs, the most common of which are reading disabilities (RDs).The purpose of this research is to gain a deeper understanding of the characteristics and treatment of RDs in NF1. The Investigator will evaluate four different groups (see list below) to determine if there are differential outcomes in these groups of children with NF+RD. The first two groups will consist of NF1 patients, and the second two groups will consist of participants with RDs but without NF1. 1. Reading tutoring program and a medication called Lovastatin (NF1 patients) 2. Reading tutoring program and no Lovastatin (placebo) (NF1 patients) 3. Reading tutoring program (RD participants) 4. Other Academic "Sham" tutoring (eligible to receive reading tutoring after study participation is complete) (RD participants) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02964884
Study type	Interventional
Source	Vanderbilt University
Contact	Julie Delheimer, BS
Phone	615-875-5534
Email	educationbrain@vanderbilt.edu
Status	Recruiting
Phase	Phase 2
Start date	November 2016
Completion date	July 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03190915` - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	Phase 2
Completed	`NCT03326388` - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours	Phase 1/Phase 2
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Active, not recruiting	`NCT01362803` - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT01218139` - Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients	N/A
Recruiting	`NCT05149469` - Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Not yet recruiting	`NCT02505412` - Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients	N/A
Terminated	`NCT02256124` - Effect of Lamotrigine on Cognition in NF1	Phase 2/Phase 3
Completed	`NCT01707836` - Neurofibromatosis Type 1 Brain Tumor Genetic Risk	N/A
Active, not recruiting	`NCT01218152` - Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs	N/A
Recruiting	`NCT03975829` - Pediatric Long-Term Follow-up and Rollover Study	Phase 4
Recruiting	`NCT05186870` - Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Active, not recruiting	`NCT03231306` - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas	Phase 2
Withdrawn	`NCT03332030` - Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Recruiting	`NCT05388370` - PASS of Paediatric Patients Initiating Selumetinib
Recruiting	`NCT02777775` - Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Completed	`NCT02944032` - Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1	N/A
Completed	`NCT01851135` - Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1	N/A
Completed	`NCT01410006` - Neurofibromatosis Type 1 Patient Registry	N/A
Active, not recruiting	`NCT00326872` - AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine	Phase 2